BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Pluristem Life Systems Inc. To Present At The 10th Annual Meeting Of The International Society for Cellular Therapy (ISCT), Dublin, Ireland


10/19/2005 5:11:05 PM

HAIFA, Israel--(BUSINESS WIRE)--April 28, 2004--Pluristem Life Systems, Inc. -- (OTCBB:PLRS), a biotechnology company dedicated to the expansion of stem cells from umbilical cord blood to address a myriad of fatal illnesses, today announced that the Company has been chosen to present at the 10th Annual Meeting of The International Society for Cellular Therapy (ISCT) that will be held in Dublin, Ireland on May 7-10, 2004.

Pluristem will present laboratory results demonstrating the significant superiority of three-dimensional (3-D) cultures over the conventional two-dimensional (2-D) cultures presently used in most stem cell expansion research. The results confirm the unique quality and potential of Pluristem's proprietary 3-D PluriX(TM) bioreactor.

Pluristem's core technology is designed to expand hematopoietic stem cells from umbilical cord blood for bone marrow transplantations using its proprietary PluriX(TM) bioreactor system. The uniqueness of the PluriX(TM) bioreactor is its ability to create a 3-D microenvironment that closely resembles the structure and function of the body's bone marrow environment. The PluriX(TM) bioreactor, consisting of a stromal cell culture, provides an optimal environment to support and maintain hematopoietic stem cells (HSC). These vital early stage stem cells have the distinct capacity to self-renew, expand and differentiate or evolve into different types of blood cells. They are exclusively required for bone marrow transplants and are the only cells that can reconstitute the hematopoietic system following bone marrow transplantation.

Bone marrow transplants (BMT) offer an ultimate treatment for many blood and immune system diseases. Today BMT using cord blood have achieved limited success due to the small volume of blood that can be collected from the umbilical cord. As recently announced, the PluriX(TM) bioreactor can produce from one donation of HSC from cord blood sufficient quantities for a number of adult transplants.

"We are honored to once again be chosen to present at an international forum of our esteemed peers. As Pluristem moves into the final stage of pre-clinical trials, this exposure can strengthen our alliances and exposure within the scientific community as well as create opportunities for future technology and business collaborations," stated Dr. Irit Arbel, CEO.

About ISCT

The ISCT is a professional organization for those working or interested in cell-based research, processing, manipulation and clinical translation. The ISCT serves as a global forum and voice for clinicians, scientists, regulatory and laboratory personnel, and other parties engaged or interested in basic research and development, translational studies, and the clinical application of all cellular based therapies.

About Pluristem

Pluristem is a biotechnology company dedicated to the development of stem cell expansion technology. The Company is concentrating on the expansion of cord blood hematopoietic stem cells (blood and immune system cells) to provide vital stem cell expansion services to blood banks and transplants centers in the U.S. and Europe.

Safe Harbor Statement

Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding our developing stem cell technology into a useful product which, among other things, can treat fatal illnesses and obtaining patent protection in the US and worldwide for our technology. Actual outcomes and our actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to complete its obligations under the stem cell license agreement, inability to finance the planned development of the technology, unforeseen technical difficulties in developing the stem cell technology, and challenges to or failure of our patent applications, which could among other things, delay or prevent product release or our ability to protect our products from competition. For further risk factors see the Company's 10-KSB filed with the SEC for our latest completed fiscal year.

Contacts

for Pluristem Life Systems, Inc. DeMonte Associates Cynthia DeMonte, 212-605-0525 cdemonte@demonte.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES